View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 2, 2022

Tevogen Bio reports positive data from Covid-19 therapy trial

At any dose levels tested, no dose-limiting toxicities or substantial treatment-associated adverse events were reported.

Tevogen Bio has reported positive safety data following the conclusion of subject enrolment in the proof-of-concept clinical trial of its T cell therapy, TVGN-489, in elderly or ambulatory Covid-19 patients at increased risk.

The open-label trial is designed to analyse the safety and optimal dose of the therapy in ambulatory Covid-19 patients who were at greater risk for complications associated with the infection. 

It was carried out at Thomas Jefferson University Hospital in Philadelphia, US.

Patients are deemed at increased risk due to comorbid conditions such as lung, heart, liver and kidney ailments, diabetes, cancer, hypertension, obesity or aged 65 years or above with or without comorbid conditions. 

Trial subjects were given one of four escalating doses of the therapy with enrolment concluded for all levels in nine months. 

At any dose levels tested in the trial, no dose-limiting toxicities or substantial treatment-associated adverse events, including cytokine release syndrome (CRS), were reported in any trial subject. 

A lead investigational therapy of the company, TVGN-489 is a genetically unmodified, off-the-shelf, allogeneic cytotoxic CD8+ T lymphocyte (CTL) product.

It is claimed to have activity against various targets across the genome of the SARS-CoV-2 virus. 

Tevogen CEO Ryan Saadi said: “We are extremely pleased to report the successful completion of patient enrolment in the TVGN-489 proof-of-concept clinical trial and are incredibly grateful for the trial patients, research and development team, investigators, as well as our partners at Thomas Jefferson University Hospital for completing this clinical trial. 

“We are looking forward to a full review of the data in the coming weeks.”

In November last year, the company concluded the dosing of the first cohort of subjects in the proof-of-concept trial of TVGN-489 to treat Covid-19 in high-risk patients.

Cell & Gene Therapy coverage on Clinical Trials Arena is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Optimise your cell therapy process: a guide to cell thawing

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena